Oncotalks hematology videos and news

Latest news

EHA 2019 Prof. Heinz Gisslinger, MD

EHA 2019 Prof. Heinz Gisslinger, MD

Prof. Heinz Gisslinger, MD Medical University of Vienna, Vienna, Austria commenting on REAL-WORLD SAFETY DATA FROM A NONINTERVENTIONAL LONG-TERM POSTAUTHORIZATION SAFETY STUDY OF RUXOLITINIB IN MYELOFIBROSIS which was presented at EHA 2019 in AmsterdamReferences: EHA Library. BARRACO F. Jun 14, 2019; 266478Link to abstract: https://library.ehaweb.org/eha/2019/24th/266478/fiorenza.barraco.real-world.safety.data.from.a.noninterventional.long-term.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DREAL-WORLD+SAFETY+DATA+FROM+A+NONINTERVENTIONAL+LONG-TERM+POSTAUTHORIZATION+SAFETY+STUDY+OF+RUXOLITINIB+IN+MYELOFIBROSIS
EHA , Lithuania , Albania
00:04:02
EHA 2019 Chinmay Munje, MD, PhD

EHA 2019 Chinmay Munje, MD, PhD

Chinmay Munje, MD, PhD from the Paul O’Gorman Leukaemia Research Centre, Glasgow, UK is commenting on the publication "COMBINATION OF ASCIMINIB (ABL001) WITH ATP-COMPETITIVE TYROSINE KINASE INHIBITORS TARGETS EARLY CML PROGENITOR CELLS", which was presented at EHA 2019 in AmsterdamReference: EHA Library. BARRACO F. Jun 14, 2019; 266478https://library.ehaweb.org/eha/2019/24th/266478/fiorenza.barraco.real-world.safety.data.from.a.noninterventional.long-term.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DREAL-WORLD+SAFETY+DATA+FROM+A+NONINTERVENTIONAL+LONG-TERM+POSTAUTHORIZATION+SAFETY+STUDY+OF+RUXOLITINIB+IN+MYELOFIBROSIS
EHA , Lithuania , Albania
00:04:34
EHA 2019 Ruben Mesa, MD, FACP

EHA 2019 Ruben Mesa, MD, FACP

Ruben Mesa, MD, FACP from the UT Health San Antonio MD Anderson, San Antonio, USA is commenting on BODY MASS INDEX AND TOTAL SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASMS - DISCOVERY OF A U-SHAPED ASSOCIATION, which was presented at EHA 2019 in AmsterdamReference: EHA Library. Scheber R. Jun 14, 2019; 266475https://library.ehaweb.org/eha/2019/24th/266475/robyn.scheber.body.mass.index.and.total.symptom.burden.in.myeloproliferative.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DBODY+MASS+INDEX+AND+TOTAL+SYMPTOM+BURDEN+IN+MYELOPROLIFERATIVE+NEOPLASMS+-+DISCOVERY+OF+A+U-SHAPED+ASSOCIATION
EHA , Lithuania , Hungary , Albania
00:04:45
ASCO 2019 Dr. Razvan Curca

ASCO 2019 Dr. Razvan Curca

Dr. Razvan Curca from the Spitalul Judetean de Urgenta, Alba Iulia is commenting on two publications presented at ASCO 2019 in ChicagoNathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)Schadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)TAF-ADV-2-06.2019
ASCO , Lithuania , Hungary , Albania
00:08:53

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies . If you require further information and/or do not wish to have cookies placed when using the site, visit Privacy Notice.

On acceptance: use all cookie settings
On denial: use only necessary cookies